A CASE OF TYROSINE KINASE INHIBITOR (DASATINIB)-INDUCED ANGIOEDEMA

被引：0
|
作者：
Peterson, J.
Toro, J.
Welch, N.
Lalmuanpuii, J.
Tarbox, J.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2023年 / 131卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
M045
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 50 条
  • [41] Dasatinib, a selective tyrosine kinase inhibitor, prevents joint destruction in rheumatoid arthritis animal model
    Min, Hong Ki
    Kim, Se Hee
    Won, Ji-Yeon
    Kim, Kyoung-Woon
    Lee, Ji-Yeon
    Lee, Sang-Heon
    Kim, Hae-Rim
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (04) : 718 - 726
  • [42] TRANSPORT AND KINASE DEPENDENT REGULATION OF TYROSINE KINASE INHIBITOR INDUCED CARDIOTOXICITY
    Xu, V.
    Pasquariello, K.
    Karzoun, L.
    Sparreboom, A.
    Sprowl, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S12 - S12
  • [43] Tyrosine Kinase Inhibitor Induced Interstitial Lung Disease
    Abid, H.
    Siddiqui, N.
    Thirukonda, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [44] Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
    Agrawal, Vineet
    Christenson, Eric S.
    Showel, Margaret M.
    CASE REPORTS IN ONCOLOGY, 2015, 8 (01): : 87 - 92
  • [45] Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
    El-Dabh, Ashraf
    Acharya, Deepak
    PULMONARY CIRCULATION, 2019, 9 (03)
  • [46] The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
    Yue Gu
    Elisa Avolio
    Valeria V Alvino
    Anita C Thomas
    Andrew Herman
    Poppy J Miller
    Niall Sullivan
    Ashton Faulkner
    Paolo Madeddu
    Cardiovascular Diabetology, 22
  • [47] The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
    Gu, Yue
    Avolio, Elisa
    Alvino, Valeria V.
    Thomas, Anita C.
    Herman, Andrew
    Miller, Poppy J.
    Sullivan, Niall
    Faulkner, Ashton
    Madeddu, Paolo
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [48] Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Hennigs, Jan K.
    Keller, Gunhild
    Baumann, Hans Joerg
    Honecker, Friedemann
    Kluge, Stefan
    Bokemeyer, Carsten
    Bruemmendorf, Tim H.
    Klose, Hans
    BMC PULMONARY MEDICINE, 2011, 11
  • [49] Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Jan K Hennigs
    Gunhild Keller
    Hans Jörg Baumann
    Friedemann Honecker
    Stefan Kluge
    Carsten Bokemeyer
    Tim H Brümmendorf
    Hans Klose
    BMC Pulmonary Medicine, 11
  • [50] He tyrosine kinase inhibitor dasatinib suppresses IGE-dependent activation and histamine release in basophils
    Kneidinger, M.
    Gleixner, K. V.
    Boehm, A.
    Vales, A.
    Sonneck, K.
    Florian, S.
    Weghofer, M.
    Lupinek, C.
    Vrtala, S.
    Valenta, R.
    Superti-Furga, G.
    Lee, F. Y.
    Valent, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 112 - 112
12345